With new rules, FDA aims to spark competition, lower prices for expensive gene therapies

Stat News

28 January 2020 - The FDA released a slew of gene therapy policies Tuesday aimed at encouraging drug makers to bring more of the medicines to market and perhaps forcing them to lower their prices.

The FDA has approved just four gene therapies since 2017, and each has carried a sky-high price tag. 

The FDA’s most recent approval, AveXis’ Zolgensma, costs $2.1 million, the most expensive drug in history.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Gene therapy